Haemonetics corporation (HAE)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Apr'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09
Cash Flows from Operating Activities:
Net income

76,526

79,737

68,119

49,359

55,019

46,064

21,240

22,616

45,572

-17,448

4,492

4,215

-26,268

16,137

-58,696

-65,658

-55,579

-49,774

25,654

20,279

16,897

30,011

30,313

39,373

35,148

37,525

31,139

21,139

38,800

44,045

52,393

59,726

66,886

70,068

71,551

79,009

79,980

62,953

61,504

58,215

58,370

0

0

0

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization

110,289

111,305

112,195

110,440

109,418

102,617

96,953

93,873

89,247

88,469

88,466

88,978

89,733

89,721

90,166

90,200

89,911

89,883

89,426

87,797

86,053

86,568

85,109

83,894

81,740

77,803

75,127

72,658

65,481

59,451

53,957

49,158

49,966

48,376

48,074

47,723

48,145

48,480

47,227

45,588

43,236

0

0

0

Impairment of assets

50,599

50,597

48,721

48,721

21,170

23,625

23,843

23,843

2,673

72,153

72,843

73,582

75,348

19,608

103,660

103,009

101,243

89,679

5,491

5,616

5,877

2,122

1,386

2,521

2,587

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Share-based compensation expense

20,454

19,500

18,957

18,539

17,188

18,408

16,787

15,061

13,025

9,902

9,114

8,653

9,150

7,358

7,301

5,625

6,949

10,075

11,040

13,770

14,095

13,637

13,604

13,558

13,082

12,702

12,371

11,565

10,969

10,490

9,599

9,302

9,286

9,392

11,422

11,014

10,810

10,837

9,364

9,685

10,267

0

0

0

Deferred tax (benefit) provision

-6,958

-3,726

6,061

8,042

13,351

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal

-

-

-

-

-

-

-

-

-

8,000

8,000

8,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for losses on accounts receivable and inventory

373

-3,355

-295

1,085

2,111

2,914

69

-1,072

208

497

5,167

9,738

11,381

20,396

16,875

13,882

13,053

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

1,857

1,954

1,566

1,139

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on sale of property, plant and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-380

-398

-395

-351

-964

-712

-826

-772

-835

-636

-745

-674

612

-28

351

435

0

0

0

Unrealized (gain) loss from hedging activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,645

2,786

-294

-1,268

-1,558

-998

1,840

2,800

128

-434

-2,800

-2,908

-700

582

748

-125

-166

811

667

882

614

-1,772

2,380

2,010

1,368

0

0

0

Changes in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,918

-431

194

148

45

0

0

0

-

-

-

-

2,154

1,580

1,580

1,970

1,894

0

0

0

-

-

-

-

Other non-cash operating activities

-1,234

4,705

2,661

3,829

3,798

4,763

5,088

3,484

4,123

42

2,413

2,168

860

1,253

-1,087

-22

899

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Reversal)/accretion of interest expense on contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Contingent consideration expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Change in accounts receivable

-18,863

4,505

16,932

13,969

38,064

22,869

18,978

-1,307

-5,087

-7,481

-7,087

2,881

-3,155

2,264

3,234

8,613

10,328

10,162

1,986

-7,052

-8,446

-53

-7,519

119

-6,063

-14,517

6,705

32,000

38,080

41,243

31,893

10,458

10,539

5,141

4,415

-3,364

3,920

59

-5,313

-6,241

-4,364

0

0

0

Change in inventories

84,721

95,949

94,849

61,678

39,322

14,699

-3,189

2,090

-14,385

-29,868

-18,393

-3,586

1,552

4,855

725

-10,585

-11,896

818

8,370

14,356

21,515

8,892

9,460

12,337

15,613

30,580

34,575

14,490

18,685

22,213

20,586

39,280

32,528

25,480

14,050

8,681

2,560

2,089

3,494

5,207

1,665

0

0

0

Change in prepaid income taxes

-

-

-

6,894

-

-

-

-691

-1,436

-1,332

-2,495

-3,144

-1,395

780

793

1,214

651

-11,878

-12,508

-10,606

-10,662

-3,080

-606

-5,589

-1,175

4,476

3,287

8,297

4,025

13,564

11,422

5,390

-3,058

-6,060

-7,114

-3,056

-1,680

-12,371

-20,010

-20,608

-7,254

0

0

0

Change in other assets and other liabilities

2,876

8,377

15,456

6,500

-494

308

-17,496

-7,458

-17,670

-490

17,169

10,381

18,253

4,497

-6,294

-548

-3,121

-17,443

190

3,725

8,013

20,877

10,051

3,523

-3,176

-3,521

-3,217

-5,402

6,187

459

-86

-736

-3,156

5,360

-1,990

-1,062

470

9,921

18,740

22,033

13,809

0

0

0

Tax benefit of exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,786

-296

1,165

1,094

1,649

3,195

3,044

3,984

4,194

4,453

3,494

2,652

1,958

1,507

4,947

4,759

4,941

6,307

3,439

3,035

2,670

0

0

0

Change in accounts payable and accrued expenses

-17,308

-5,782

-6,150

-12,163

17,736

29,271

43,631

46,353

41,401

18,797

8,088

949

21,072

30,065

3,003

3,192

-30,239

-32,652

-27,609

-17,485

1,993

11,079

16,787

2,159

477

-12,581

-1,604

27,809

25,581

43,835

34,876

17,708

19,413

10,408

1,401

-7,505

-18,683

-15,616

-9,398

-4,707

5,263

0

0

0

Net cash provided by operating activities

158,217

132,449

111,331

138,787

159,281

196,270

203,501

205,047

220,350

197,300

187,106

167,468

159,738

178,414

155,064

143,310

121,865

123,917

118,959

122,690

127,178

123,344

141,742

139,860

139,524

115,595

94,269

97,923

85,074

91,507

96,346

88,740

115,318

113,482

131,708

137,060

123,455

128,003

113,475

118,488

130,668

0

0

0

Cash Flows from Investing Activities:
Capital expenditures

48,758

51,828

60,681

99,696

118,961

124,348

121,676

88,592

74,799

71,314

63,636

67,377

76,135

89,051

93,899

100,638

102,405

95,561

101,478

109,381

122,220

130,457

116,318

97,641

73,648

56,224

55,958

66,839

62,188

65,924

63,787

49,838

53,198

48,642

46,424

43,246

46,669

46,414

47,512

50,324

56,304

0

0

0

Proceeds from divestiture

9,808

9,808

9,808

9,808

0

0

0

0

9,000

9,000

9,000

9,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of property, plant and equipment

16,774

16,762

17,896

2,865

2,813

3,445

2,068

2,027

2,758

2,676

3,971

3,716

2,822

2,013

541

608

637

462

368

504

452

678

223

-17

488

875

2,255

2,285

1,968

1,775

1,227

1,235

1,002

1,651

1,336

1,376

1,468

1,509

1,664

1,695

1,785

0

0

0

Acquisition of Whole Blood Business

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Other acquisitions and investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,000

3,000

3,000

3,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of Neoteric

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Acquisition of Medicell

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in investing activities

-57,176

-25,258

-32,977

-87,023

-116,148

-120,903

-119,608

-86,565

-63,041

-59,638

-50,665

-54,661

-73,313

-87,038

-93,358

-100,030

-104,768

-98,099

-104,110

-111,877

-121,768

-130,951

-116,934

-107,204

-105,830

-86,878

-85,565

-622,853

-596,395

-600,293

-598,704

-49,603

-52,196

-46,991

-51,445

-48,227

-51,558

-109,313

-103,900

-119,525

-132,335

0

0

0

Cash Flows from Financing Activities:
Term loan borrowings

0

0

0

0

347,780

347,780

347,780

347,780

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of term loan borrowings

13,125

17,500

13,125

17,500

266,853

274,703

291,302

303,526

61,654

56,910

52,168

47,425

42,683

45,055

40,312

28,456

21,342

14,867

8,018

8,277

8,531

37,126

37,104

37,084

37,063

57

38

16

0

-224

-200

-144

0

1,125

1,100

788

632

0

0

0

-

-

-

-

Payments on long-term real estate mortgage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net increase in short-term loans

45,000

45,000

40,000

105,000

15,000

92

254

416

671

-9,173

-49,194

-49,211

-50,727

-45,846

-5,768

-3,369

2,272

8,343

6,981

3,536

843

-1,452

-8,975

-4,096

-5,521

-1,537

8,469

7,726

7,446

2,740

937

-297

-288

-4,835

-7,912

-5,226

-15,153

-16,200

-12,643

-20,257

6,184

0

0

0

Repayment of term loan borrowings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from employee stock purchase plan

3,369

3,368

3,304

3,304

3,254

3,254

3,404

3,404

3,246

3,246

3,203

3,202

3,560

3,561

4,057

4,058

4,341

4,340

4,496

4,496

4,763

4,763

5,093

5,093

5,229

5,229

4,703

4,703

4,142

4,143

3,981

3,979

3,723

3,720

3,883

3,885

3,681

3,683

3,070

3,097

2,909

0

0

0

Proceeds from exercise of stock options

8,647

8,457

9,110

10,995

10,191

13,301

34,101

33,495

37,094

44,398

26,025

34,458

29,437

21,821

19,190

12,548

14,032

11,853

13,622

9,960

9,290

11,452

11,150

11,599

15,225

10,874

11,985

20,120

27,517

34,741

34,417

26,046

15,475

17,809

39,762

40,561

40,896

44,355

19,723

19,371

17,270

0

0

0

Excess tax benefit on exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,019

3,603

3,950

4,101

3,752

3,179

2,231

1,433

2,801

2,829

2,888

3,124

1,403

892

814

421

0

0

0

Share repurchases

-

-

0

155,000

-

-

180,000

180,000

100,000

0

0

0

-

-

-

-

60,984

61,316

66,247

51,599

39,033

38,701

33,770

26,466

0

0

0

0

-

-

-

-

-

-

-

-

50,000

50,000

83,669

90,000

40,000

0

0

0

Other financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Net cash used in financing activities

-131,208

-135,585

-165,639

-53,201

-50,628

-170,276

-85,763

-98,431

-120,643

-18,439

-72,134

-58,976

-60,413

-65,617

-23,218

-37,838

-62,624

-44,453

-41,685

-34,121

-33,160

-41,709

-52,287

-59,014

-20,699

-43,853

-36,827

455,130

461,853

496,282

506,095

-18,710

-30,470

-31,628

-12,536

41,320

-18,084

-17,337

-73,178

-87,751

-13,970

0

0

0

Effect of exchange rates on cash and cash equivalents

-1,873

-60

-448

-435

-3,323

-1,811

-1,989

316

3,939

2,729

445

-340

-1,571

-1,287

135

602

-12

-1,398

-2,888

-4,431

-4,057

-3,330

-1,698

-27

354

-199

220

81

-273

313

-107

-1,271

-498

971

645

3,271

1,332

-808

330

-1,567

478

0

0

0

Net Change in Cash and Cash Equivalents

-32,040

-28,454

-87,733

-1,872

-10,818

-96,720

-3,859

20,367

40,605

121,952

64,752

53,491

24,441

24,472

38,623

6,044

-45,539

-20,033

-29,724

-27,739

-31,807

-52,646

-29,177

-26,385

13,349

-15,335

-27,903

-69,719

-49,741

-12,191

3,630

19,156

32,154

35,834

68,372

133,424

55,145

545

-63,273

-90,355

-15,159

0

0

0

Supplemental Disclosures of Cash Flow Information:
Interest paid

12,545

14,363

13,543

14,290

13,116

11,471

9,728

8,199

7,663

7,476

7,500

7,603

7,850

8,363

8,467

8,515

8,511

8,432

8,479

8,554

8,497

8,240

8,400

8,552

8,942

8,863

8,944

8,227

5,910

4,112

1,882

396

414

436

456

461

487

511

531

561

563

0

0

0

Income taxes paid

11,507

11,860

11,687

9,466

8,205

7,996

8,687

8,749

9,083

8,553

8,539

7,567

6,957

7,669

7,040

7,745

7,829

6,368

7,516

10,739

11,211

13,895

11,946

8,452

7,261

8,371

9,506

10,890

13,178

13,566

15,814

12,571

10,764

12,772

12,016

16,406

16,669

15,993

22,100

20,189

21,519

0

0

0

Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placement of Haemonetics equipment

14,479

14,950

10,026

17,519

16,345

15,639

17,097

9,424

8,963

6,598

6,743

5,829

6,255

5,485

7,590

8,502

9,663

10,962

8,982

7,940

7,458

8,372

8,576

9,670

10,584

10,038

16,544

17,798

21,677

27,027

23,208

22,419

18,333

12,073

7,651

7,128

5,069

7,623

8,734

6,900

7,833

0

0

0